<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We divided patients with <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">brain lesions</z:e> into three groups: (a) patients with primary or metastatic <z:e sem="disease" ids="C0153633" disease_type="Neoplastic Process" abbrv="">brain cancer</z:e>, (b) <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e>, and (c) brain <z:mp ids='MP_0009275'>contusion</z:mp>(s) </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed each patient's sera for <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase isoenzyme BB (CK-BB), using a monoclonal antibody kit (Impres-BB; International Immunoassay Laboratories) </plain></SENT>
<SENT sid="2" pm="."><plain>Computerized axial tomography (CAT) scans were performed on each patient </plain></SENT>
<SENT sid="3" pm="."><plain>The size of the various lesions was measured from the CAT scan and recorded in milliliters </plain></SENT>
<SENT sid="4" pm="."><plain>Total CK, CK-BB, and their ratios were compared with the volume of damaged brain tissue </plain></SENT>
<SENT sid="5" pm="."><plain>We found no correlation between any of the variables and the various <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">brain lesions</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>We attribute this lack of correlation to an intact blood-brain barrier, the rapid elimination or inactivation of CK-BB, or some combination of these factors </plain></SENT>
</text></document>